Also trades as: 4DX.AX (ASX) · $vol 17M
FDMDF OTC
4DMedical Limited
1W: +9.1%
1M: +1.7%
3M: +7.1%
YTD: +27.7%
1Y: +129.0%
3Y: +1251.3%
$3.00
+0.25 (+9.09%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.8B
52W Range0.8701-5
Volume1,000
Avg Volume2,617
Beta1.97
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAndreas Fouras
Employees181
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-02-02
Website4dmedical.com
Melbourne Connect
Carlton, VIC 3053
AU
Carlton, VIC 3053
AU
61 3 9545 5940
About 4DMedical Limited
4DMedical Limited operates as a medical technology firm with operations spanning both Australia and the United States. A core aspect of its business involves the commercialization of XV Technology, an advanced four-dimensional system for lung imaging. The company's offerings further extend to a software-as-a-service (SaaS) delivery model, alongside its proprietary XV lung ventilation analysis software. Additional products include Permetium, a preclinical imaging system designed to quantify localized changes in pulmonary function, and the AccuVent 200, a ventilator specifically tailored for small animals. Established in 2012, 4DMedical Limited is headquartered in Carlton, Australia.
Latest News
4DMedical and Azra AI join forces to advance lung care pathways
Azra AI and 4DMedical Partner to Bring Enterprise-Wide Lung Health Intelligence to Health Systems
4DMedical erhält TGA-Zulassung für CT:VQ™ und bringt damit kontrastmittelfreie Ventilations-/Perfusionsbildgebung nach Australien
4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
Recent Insider Trades
No insider trades found